The U.S. officials said Thursday that while speaking about reduced treatment choices in the infectious Omicron wave, the President Joe Biden government has procured abundant of still not approved antibody medication for the treatment of 600K coronavirus patients.

Xavier Becerra, the U.S. Secretary for Health and Human Services, said that the latest monoclonal antibody drug from Indianapolis-based pharmaceutical firm Eli Lilly and Company would be transported to states at no cost if the U.S. FDA (Food and Drug Administration) authorizes the request of the drug company for Emergency-Use Authorization. In addition, they’re going to make an effort to meet the demand.

The Biden administration’s action comes after the two top monoclonal antibody (mAb) cures in America turned out to be unproductive against the highly contagious Omicron variant of SARS-CoV-2, which now accounts for almost all coronavirus infections in the U.S. Data shows that the Eli Lilly is effective against the more virulent Omicron, including the newly emerged BA. 2 mutated version. The pharmaceutical giant said the indenture for its latest treatment known as “bebtelovimab (LY-CoV1404)” is worth nearly 720M dollars.

Furthermore, laboratory manufactured mAb stand-in for the immune response by blocking the lethal virus. Offered by an intravenous (IV) injection, the drugs are meant to be managed early in an infection to anticipate serious disease and fatality. For example, Donald Trump, the former US President, got an antibody combination after he tested COVID-19-positive in 2020.

New COVID-19 Treatments in Short Supply

However, late in January, the Food and Drug Administration withdrew its EUA for Regeneron antibody treatment, along with one more from Eli Lilly. The two treatments had been the chief support of the antibody-drug, and medics were closely pursued to come up with alternatives when they did not work effectively against the highly transmissible Omicron.

Alternative treatments for early coronavirus infections, including two new antiviral tablets, molnupiravir and Paxlovid, from Merck and Pfizer, respectively, have been in limited supply. An antibody treatment from GSK and Vir that remained productive against Omicron is also in short supply. The matter has had political implications because some GOP governors profoundly promoted the initial antibody drugs. Ron DeSantis, the governor of Florida, asserted two antibody treatments that were wavered against the Omicron variant could still benefit some sufferers.

In addition, Becerra said they want to ensure that the drugs they offer work. If someone wants to propose to US citizens that they go elsewhere, that isn’t where they’re going. Researchers say drugs to treat COVID-19 like monoclonal antibodies aren’t alternatives for immunization. Instead, they’re typically reserved for individuals who are the most susceptible, including senior citizens, people with diabetes and cardiac diseases, and transplant recipients. Eli Lilly and Company is looking for FDA approval for its antibody treatment to be used to cure mild-to-moderate coronavirus disease in increased-risk patients.

Under the contract of the US administration with Eli Lilly, Health and Human Services Department would get nearly 300K courses of new antibody treatment in this month. But, additional 300K treatment courses will be available in March, and drugs will be ready to deliver following U.S. FDA approval.

Read Also: Covid-19 Treatments from Merck, Pfizer, GSK Reasonably Priced in America – ICER